Literature DB >> 11009083

Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen.

A Prévost-Blondel1, M Neuenhahn, M Rawiel, H Pircher.   

Abstract

Perforin-mediated lysis and secretion of IFN-gamma belong to the key effector functions of CD8 T cells. To compare the anti-tumor activity of these two mechanisms, we used B16.F10 melanoma cells (B16GP33) expressing the cytotoxic T cell epitope GP33 and T cell receptor transgenic (TCR-tg) mice specific for GP33 and deficient in perforin or IFN-gamma. B16GP33 tumor cells, injected either i.v. to induce experimental metastases or s.c., were similarly controlled in both wild-type and perforin-deficient, but not in IFN-gamma-deficient TCR-tg mice. A similar result was obtained when the therapeutic efficacy of adoptively transferred TCR-tg effector cells from these mice was examined in the corresponding perforin- or IFN-gamma-deficient C57BL/6 hosts. Criss-cross experiments further revealed that IFN-gamma production by the host strongly influenced the efficiency of the adoptively transferred effector cells. In contrast to the potent ability of GP33-specific effector cells to mediate B16GP33 tumor regression without perforin, GP33-specific memory cells, induced with recombinant vaccinia virus expressing GP33, failed to control B16GP33 tumor growth in the absence of perforin. In conclusion, our data demonstrate a crucial role for IFN-gamma in B16GP33 tumor cell elimination in vivo and indicate a differential requirement of perforin by effector versus memory CD8 T cells in anti-tumor immunity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11009083     DOI: 10.1002/1521-4141(200009)30:9<2507::AID-IMMU2507>3.0.CO;2-V

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

1.  Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.

Authors:  Willem W Overwijk; Karin E de Visser; Felicia H Tirion; Laurina A de Jong; Thijs W H Pols; Yme U van der Velden; Jasper G van den Boorn; Anna M Keller; Wim A Buurman; Marc R Theoret; Bianca Blom; Nicholas P Restifo; Ada M Kruisbeek; Robert A Kastelein; John B A G Haanen
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

2.  Intensity of the vaccine-elicited immune response determines tumor clearance.

Authors:  Ainhoa Perez-Diez; Paul J Spiess; Nicholas P Restifo; Polly Matzinger; Francesco M Marincola
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

3.  Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy.

Authors:  Aki Furusawa; John Reiser; Kavitha Sadashivaiah; Haley Simpson; Arnob Banerjee
Journal:  J Immunother       Date:  2018 Feb/Mar       Impact factor: 4.456

4.  CD4 cells can be more efficient at tumor rejection than CD8 cells.

Authors:  Ainhoa Perez-Diez; Nathalie T Joncker; Kyungho Choi; William F N Chan; Colin C Anderson; Olivier Lantz; Polly Matzinger
Journal:  Blood       Date:  2007-02-27       Impact factor: 22.113

5.  Chemogenetic modulation of sensory neurons reveals their regulating role in melanoma progression.

Authors:  Pedro A C Costa; Walison N Silva; Pedro H D M Prazeres; Caroline C Picoli; Gabriela D A Guardia; Alinne C Costa; Mariana A Oliveira; Pedro P G Guimarães; Ricardo Gonçalves; Mauro C X Pinto; Jaime H Amorim; Vasco A C Azevedo; Rodrigo R Resende; Remo C Russo; Thiago M Cunha; Pedro A F Galante; Akiva Mintz; Alexander Birbrair
Journal:  Acta Neuropathol Commun       Date:  2021-11-16       Impact factor: 7.801

6.  Mannan-modified adenovirus encoding VEGFR-2 as a vaccine to induce anti-tumor immunity.

Authors:  Jie Zhang; Ying Wang; Yang Wu; Zhen-Yu Ding; Xin-Mei Luo; Wu-Ning Zhong; Jie Liu; Xiang-Yu Xia; Guo-Hua Deng; Yao-Tiao Deng; Yu-Quan Wei; Yu Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-14       Impact factor: 4.553

7.  CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors.

Authors:  Angela M Tatum; Lawrence M Mylin; Susan J Bender; Matthew A Fischer; Beth A Vigliotti; M Judith Tevethia; Satvir S Tevethia; Todd D Schell
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

8.  Adoptive immunotherapy with Cl-IB-MECA-treated CD8+ T cells reduces melanoma growth in mice.

Authors:  Antonella Montinaro; Giovanni Forte; Rosalinda Sorrentino; Antonio Luciano; Giuseppe Palma; Claudio Arra; Ian M Adcock; Aldo Pinto; Silvana Morello
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

9.  CD40-activated B cells can efficiently prime antigen-specific naïve CD8+ T cells to generate effector but not memory T cells.

Authors:  Mélissa Mathieu; Natacha Cotta-Grand; Jean-François Daudelin; Salix Boulet; Réjean Lapointe; Nathalie Labrecque
Journal:  PLoS One       Date:  2012-01-23       Impact factor: 3.240

10.  Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site.

Authors:  Maxime Thoreau; HweiXian Leong Penny; KarWai Tan; Fabienne Regnier; Julia Miriam Weiss; Bernett Lee; Ludger Johannes; Estelle Dransart; Agnès Le Bon; Jean-Pierre Abastado; Eric Tartour; Alain Trautmann; Nadège Bercovici
Journal:  Oncotarget       Date:  2015-09-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.